1. Home
  2. NDRA

as of 12-12-2025 3:18pm EST

$5.42
$0.08
-1.45%
Stocks Health Care Biotechnology: Electromedical & Electrotherapeutic Apparatus Nasdaq

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Chart Type:
Time Range:
Founded: 2007 Country:
United States
United States
Employees: N/A City: ANN ARBOR
Market Cap: 7.3M IPO Year: 2017
Target Price: $30.00 AVG Volume (30 days): 114.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -12.43 EPS Growth: N/A
52 Week Low/High: $2.90 - $11.96 Next Earning Date: 11-17-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered NDRA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 16 hours ago

AI Recommendation

hold
Model Accuracy: 67.57%
67.57%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Latest ENDRA Life Sciences Inc. News

NDRA Breaking Stock News: Dive into NDRA Ticker-Specific Updates for Smart Investing

All NDRA News

Share on Social Networks: